Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabre Insurance Group Regulatory News (SBRE)

Share Price Information for Sabre Insurance Group (SBRE)

Share Price is delayed by 15 minutes
Get Live Data
157.60    3.80 (2.47%)
Bid:
157.60
Ask:
158.00
Spread: 0.40 (0.254%)
Market Cap: £385.03m
SBRE Live PriceLast checked at - London Stock Exchange

Intraday Sabre Insurance Group Share Chart

Trading Update

22 May 2025 07:00

RNS Number : 6675J
Sabre Insurance Group PLC
22 May 2025
 

Sabre Insurance Group plc

Trading Update

Active optimisation of premium growth and profit through the cycle

 

Sabre Insurance Group plc (the "Group" or "Sabre"), one of the UK's leading motor insurance underwriters, today provides an update on trading for the period from 1 January 2025 to 30 April 2025 ahead of its Annual General Meeting ("AGM") later this morning.

Unaudited

Unaudited

 

4 months ended

4 months ended

 

 30 Apr 2025

 30 Apr 2024

Gross written premium - Motor Vehicle

£58.1m

£77.1m

Gross written premium - Motorcycle

£3.3m

£3.5m

Gross written premium - Taxi

£4.7m

£5.1m

Gross written premium - Total

£66.1m

£85.7m

Business highlights for the first four months of 2025

‒ Good premium volume being written in the first four months of the year against historic norms

‒ Total gross written premium of £66.1m up over 8% on the prior 5-year average of £61.0m for the same period. Core Motor Vehicle gross written premium of £58.1m over 7% up on the prior 5-year average of £54.2m for the same period

‒ Comparator period in Q1 2024 was a period of extraordinary growth

‒ Long-term commitment to profit over volume underpins our approach to managing Sabre through the cycle

‒ Loss ratio remains in-line with target

‒ Post-dividend solvency capital ratio well above the Group's last reported figure of 171.1% at 31 December 2024 reflecting strong profitability year-to-date

‒ Successful launch of Sabre Direct Motorcycle product, expanding distribution and strengthening our presence in the Motorcycle market

‒ Good progress towards enhanced pricing infrastructure with testing planned for H2 2025

Market trends

‒ Market pricing data suggests that decreases have flattened across the Motor Vehicle market

‒ Anticipate market premium increases later in 2025 in response to 12-month market price reductions of c.15%, set against continued high levels of inflation

‒ Claims inflation for 2025 anticipated to remain at high single-digits as previously guided

Full-year guidance reiterated

‒ Outlook for the full-year and delivering on our 2030 targets is underpinned by a commitment to profit over volume

‒ Anticipate good profit and dividends in 2025 despite weak market conditions in the year to date

‒ Undiscounted net insurance margin expected to be within our target 18% to 22% range

‒ Premium growth for the remainder of 2025 dependent on market conditions. Current expectation of a slight decrease in total premium year-on-year

‒ On-track to deliver our target of at least £80m of profit before tax in 2030

 

Geoff Carter, Chief Executive Officer of Sabre, commented:

"I am pleased that Sabre remains on track to deliver target margins and strong profit for the year, despite the relatively weak pricing environment that we have seen in 2025 to date. We have managed the insurance cycle in line with our successful long-term strategy and have reduced the volume of business written during this less attractive period. It is worth noting that our reported premium for this period compares the peak of the previous cycle against the weakest part of the current pricing cycle.

We have, however, continued to write healthy levels of business at strong margins and are very well positioned to return to growth when pricing inevitably corrects. Maintaining pricing discipline means that we are confident of delivering strong profitability and a good dividend this year.

The Sabre Direct Motorcycle product has now launched, thanks to a terrific effort by our team. We are currently writing a limited amount of premium as we move through our initial "test and learn" phase.

We have also progressed development of our enhanced pricing infrastructure, which is integral to the next stage of our Ambition 2030 plan. This remains on-track for testing later this year and is expected to begin positively impacting the top-line later, in 2026.

Overall, the Group is performing well through this current period of market weakness and will be in a position of strength, ready to grow the core motor book, and accelerate the development of our motorcycle product. We remain on-track to deliver our target of at least £80m of profit before tax in 2030".

 

Investor enquiries

01306 747 272

Sabre Insurance Group plc

Geoff Carter / Adam Westwood

Media enquiries

020 7353 4200

Teneo

sabre@teneo.com

James Macey White / Ffion Dash

 

LEI Code: 2138006RXRQ8P8VKGV98

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSEDFMFEISEFI
Date   Source Headline
12th Apr 20214:41 pmRNSNotice of AGM
7th Apr 20212:16 pmRNSDirector/PDMR Shareholding
30th Mar 20211:56 pmRNSDirector/PDMR Shareholding
26th Mar 20218:24 amRNSDirector/PDMR Shareholding
16th Mar 20217:03 amRNSFinal Results
12th Mar 20217:00 amRNSNotice of Results
11th Mar 202110:37 amRNSDirector/PDMR Shareholding
1st Mar 20213:56 pmRNSHolding(s) in Company
23rd Feb 202110:40 amRNSNotice of Results
11th Feb 202110:28 amRNSDirector/PDMR Shareholding
1st Feb 202110:02 amRNSHolding(s) in Company
12th Jan 202110:53 amRNSDirector/PDMR Shareholding
8th Jan 20219:44 amRNSHolding(s) in Company
11th Dec 20201:31 pmRNSDirector/PDMR Shareholding
3rd Dec 20207:56 amRNSHolding(s) in Company
3rd Dec 20207:00 amRNSBoard Appointment
27th Nov 20204:42 pmRNSSecond Price Monitoring Extn
27th Nov 20204:37 pmRNSPrice Monitoring Extension
11th Nov 202012:07 pmRNSDirector/PDMR Shareholding
6th Nov 202011:39 amRNSHolding(s) in Company
6th Nov 202010:55 amRNSHolding(s) in Company
27th Oct 20203:47 pmRNSDirector/PDMR Shareholding
15th Oct 20207:00 amRNSDirector/PDMR Shareholding
13th Oct 20209:42 amRNSDirector/PDMR Shareholding
13th Oct 20207:00 amRNSTrading Statement
11th Sep 202010:07 amRNSDirector/PDMR Shareholding
3rd Sep 20204:13 pmRNSDirector/PDMR Shareholding
1st Sep 20202:23 pmRNSDirector/PDMR Shareholding
28th Aug 202012:02 pmRNSPrice Monitoring Extension
27th Aug 202011:32 amRNSDirector/PDMR Shareholding
19th Aug 20207:00 amRNSDirectorate Change
12th Aug 20203:50 pmRNSHolding(s) in Company
11th Aug 20201:15 pmRNSDirector/PDMR Shareholding
10th Aug 20204:00 pmRNSHolding(s) in Company
6th Aug 202012:14 pmRNSDirector/PDMR Shareholding - Correction
6th Aug 202010:11 amRNSDirector/PDMR Shareholding
6th Aug 20209:32 amRNSDirector/PDMR Shareholding
3rd Aug 202012:54 pmRNSDirector/PDMR Shareholding
28th Jul 20207:02 amRNSBoard appointment
28th Jul 20207:00 amRNSHalf-year Report
14th Jul 20204:13 pmRNSHolding(s) in Company
13th Jul 202012:51 pmRNSDirector/PDMR Shareholding
30th Jun 20201:33 pmRNSDirector/PDMR Shareholding
11th Jun 20201:59 pmRNSDirector/PDMR Shareholding
10th Jun 20209:57 amRNSDirector/PDMR Shareholding - Correction
4th Jun 20209:49 amRNSDirector/PDMR Shareholding
29th May 20203:39 pmRNSDirector/PDMR Shareholding
29th May 202012:37 pmRNSDirector/PDMR Shareholding
21st May 202012:17 pmRNSResult of AGM
21st May 20207:00 amRNSTrading Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.